Janssen COVID-19 Vaccine

GPTKB entity

Statements (51)
Predicate Object
gptkbp:instanceOf vaccine
gptkbp:administeredBy over 100 countries
gptkbp:age 18 years and older
gptkbp:approvedBy gptkb:United_States
gptkb:World_Health_Organization
gptkb:European_Medicines_Agency
gptkb:U.S._Food_and_Drug_Administration
February 27, 2021
gptkbp:ATCCode gptkb:J07BX03
gptkbp:boosterInterval at least 2 months after primary dose
gptkbp:boosterRecommended yes
gptkbp:brand gptkb:Jcovden
gptkb:Johnson_&_Johnson_COVID-19_Vaccine
gptkbp:clinicalTrialPhase gptkb:ENSEMBLE_trial
gptkbp:contains DNA encoding SARS-CoV-2 spike protein
recombinant, replication-incompetent adenovirus
gptkbp:countryOfOrigin gptkb:Netherlands
gptkb:United_States
gptkbp:developedBy gptkb:Johnson_&_Johnson
gptkb:Janssen_Pharmaceuticals
gptkbp:doseRegimen single dose
gptkbp:effect 66% against moderate to severe COVID-19 (global)
85% against severe COVID-19
gptkbp:emergencyServices February 2021
https://www.w3.org/2000/01/rdf-schema#label Janssen COVID-19 Vaccine
gptkbp:includedIn gptkb:COVAX_program
gptkbp:indication prevention of COVID-19
gptkbp:legalStatus approved in EU
approved in WHO EUL
withdrawn in US
gptkbp:notRecommendedFor children under 18
people with history of thrombosis with thrombocytopenia after previous dose
gptkbp:rareAdverseEvent gptkb:Guillain-Barré_syndrome
thrombosis with thrombocytopenia syndrome
gptkbp:routeOfAdministration intramuscular injection
gptkbp:sideEffect fever
fatigue
headache
muscle pain
pain at injection site
gptkbp:storage 2–8°C
gptkbp:storageDuration up to 3 months at 2–8°C
gptkbp:target gptkb:COVID-19
gptkbp:technology non-replicating viral vector
gptkbp:type viral vector vaccine
gptkbp:vectorFor gptkb:adenovirus_serotype_26_(Ad26)
gptkbp:WHOEmergencyUseListing March 2021
gptkbp:withdrawn gptkb:United_States
May 2023
gptkbp:bfsParent gptkb:COVID-19_vaccines_(for_Johnson_&_Johnson_and_AstraZeneca)
gptkbp:bfsLayer 6